CALGENT BIOTECHNOLOGY CO., LTD.
Update:2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati
Founded Year
2019
Unified Business No.
85127916
Status
Active
Number of Employees
0
Total Paid-in
Capital
78,333,334 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Calgent Biotechnology Co., Ltd. is a Taiwan-based biotech startup headquartered in Taipei. Founded in 2019, the company focuses on developing first-in-class small molecule therapeutics to address unmet medical needs. Calgent brings together expertise in t